Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

Oncolys and Tacere Forge Alliance to Develop RNAi HCV Drug

  • Oncolys BioPharma signed an agreement to develop Tacere Therapeutics’ drug candidate for the treatment of HCV. TT-033 is an RNAi-based product.

    Under this agreement, Oncolys has been granted an option to acquire the Asian rights for TT-033. “HCV continues to be a significant public health crisis in Japan, China, and Korea, and we look forward to Oncolys' expert guidance along the regulatory and marketing path in Asia," remarks Sara M. Hall, Tacere’s president and CEO.

    Tacere reports that it will begin IND-enabling studies on TT-033 shortly and plans to enter Phase I trials in late 2008.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »